Urinary metabolomics for noninvasive detection of borderline and acute T cell-mediated rejection in children after kidney transplantation

American Journal of Transplantation

Volumn 14, Issue 10, 2014, Pages 2339-2349

  Blydt Hansen, T D ^a   Sharma, A ^a   Gibson, I W ^a   Mandal, R ^b   Wishart, D S ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biomarker; clinical research; kidney transplantation; metabolomics; nephrology; pediatrics; practice; protocol biopsy; rejection: acute; rejection: T cell mediated (TCMR); science; translational research

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ARTICLE; BORDERLINE TUBULITIS; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INJURY SEVERITY; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY METABOLISM; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METABOLOMICS; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; T CELL MEDIATED REJECTION; T LYMPHOCYTE; URINALYSIS; URINARY METABOLOMICS; ADOLESCENT; GRAFT REJECTION; IMMUNOLOGY; URINE;

ADOLESCENT; CHILD; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MASS SPECTROMETRY; METABOLOMICS; T-LYMPHOCYTES; URINE;

EID: 84908252987     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12837     Document Type: Article

References (58)

1. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538-2545.
2. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2010 annual transplant report. Emmes Corporation, 2010.
3. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor specific HLA antibodies. Am J Transplant 2012; 12: 1157-1167.
4. Dart AB, Schall A, Gibson IW, Blydt-Hansen TD, Birk PE., Patterns of chronic injury in pediatric renal allografts. Transplantation 2010; 89: 334-340.
5. Tejani A, Sullivan EK., The impact of acute rejection on chronic rejection: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2000; 4: 107-111.
6. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2008 annual report. Emmes Corporation, 2009.
7. Joffe M, Hsu CY, Feldman HI, Weir M, Landis JR, Hamm LL., Variability of creatinine measurements in clinical laboratories: Results from the CRIC study. Am J Nephrol 2010; 31: 426-434.
8. Schwartz GJ, Work DF., Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4: 1832-1843.
9. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 2129-2134.
10. Hewitt SM, Dear J, Star RA., Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004; 15: 1677-1689.
11. Furness PN, Taub N., International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP Project. Kidney Int 2001; 60: 1998-2012.
12. Marcussen N, Olsen TS, Benediktsson H, Racusen L, Solez K., Reproducibility of the Banff classification of renal allograft pathology. Inter-and intraobserver variation. Transplantation 1995; 60: 1083-1089.
13. Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation 2011; 92: 878-882.
14. Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ., Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432-437.
15. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11: 2228-2234.
16. Kanmaz T, Feng P, Torrealba J, et al. Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation 2004; 78: 1002-1007.
17. Sigdel TK, Salomonis N, Nicora CD, et al. The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics. Mol Cell Proteomics 2013; 13: 621-631.
18. Dubinski B, Boratynska M, Kopec W, Szyber P, Patrzalek D, Klinger M., Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1)-Sensitive rejection markers in renal graft recipients. Transpl Immunol 2008; 18: 203-207.
19. Prodjosudjadi W, Daha MR, Gerritsma JS, et al. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 1996; 11: 1096-1103.
20. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol 2010; 21: 646-653.
21. Metzger J, Chatzikyrkou C, Broecker V, et al. Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl 2011; 5: 322-333.
22. Lattenist L, Kers J, Claessen N, et al. Renal and urinary levels of endothelial protein C receptor correlate with acute renal allograft rejection. PLoS ONE 2013; 8: e64994.
23. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 2013; 369: 20-31.
24. Afaneh C, Muthukumar T, Lubetzky M, et al. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation 2010; 90: 1381-1387.
25. Renesto PG, Ponciano VC, Cenedeze MA, Saraiva Camara NO, Pacheco-Silva A., High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant 2007; 7: 1661-1665.
26. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390-2397.
27. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-954.
28. Wishart DS., Metabolomics: The principles and potential applications to transplantation. Am J Transplant 2005; 5: 2814-2820.
29. Boudonck KJ, Mitchell MW, Nemet L, et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol 2009; 37: 280-292.
30. Posada-Ayala M, Zubiri I, Martin-Lorenzo M, et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int 2014; 85: 103-111.
31. Goek ON, Prehn C, Sekula P, et al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol Dial Transplant 2013; 28: 2131-2138.
32. Hauet T, Baumert H, Gibelin H., Citrate, acetate and renal medullary osmolyte excretion in urine as predictor of renal changes after cold ischaemia and transplantation. Clin Chem Lab Med 2000; 38: 1093-1098.
33. Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU., H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 2005; 67: 1142-1151.
34. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8: 1439-1444.
35. Lamers RJ, van Nesselrooij JH, Kraus VB, et al. Identification of an urinary metabolite profile associated with osteoarthritis. Osteoarthritis Cartilage 2005; 13: 762-768.
36. Rush D, Somorjai R, Deslauriers R, Shaw A, Jeffery J, Nickerson P., Subclinical rejection-a potential surrogate marker for chronic rejection-may be diagnosed by protocol biopsy or urine spectroscopy. Ann Transplant 2000; 5: 44-49.
37. Wang JN, Zhou Y, Zhu TY, Wang X, Guo YL., Prediction of acute cellular renal allograft rejection by urinary metabolomics using MALDI-FTMS. J Proteome Res 2008; 7: 3597-3601.
38. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL., Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007; 71: 1028-1035.
39. Birk PE, Blydt-Hansen TD, Dart AB, Kaita LM, Proulx C, Taylor G., Low incidence of adverse events in outpatient pediatric renal allograft biopsies. Pediatr Transplant 2007; 11: 196-200.
40. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
41. Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS ONE 2013; 8: e73076.
42. Magee L., R2 measures based on Wald and likelihood ratio joint significance tests. Amer Stat 1990; 44: 250-253.
43. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS., MetaboAnalyst 2.0-A comprehensive server for metabolomic data analysis. Nucleic Acids Res 2012; 40: W127-W133.
44. Melvik B-H, Wehrens R., The pls package: Principal component and partial least squares regression in R. J Stat Softw 2007; 18: 1-24.
45. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013. ISBN 3-900051-07-0. Available at: http://www.R-project.org/. Accessed April 21, 2014.
46. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13: 645-655.
47. Calderisi M, Vivi A, Mlynarz P, et al. Using metabolomics to monitor kidney transplantation patients by means of clustering to spot anomalous patient behavior. Transplant Proc 2013; 45: 1511-1515.
48. Wang J, Zhou Y, Xu M, Rong R, Guo Y, Zhu T., Urinary metabolomics in monitoring acute tubular injury of renal allografts: A preliminary report. Transplant Proc 2011; 43: 3738-3742.
49. Rush D, Somorjai R, Cecka MJ, et al. Urine magnetic resonance spectroscopy (UMRS): Results from the deterioration of kidney allograft function (DeKAF) study. Am J Transplant 2009; 9 (Suppl 2): 350.
50. Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 2215-2222.
51. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752.
52. Matoza JR, Danguilan RA, Chicano S., Impact of Banff borderline acute rejection among renal allograft recipients. Transplant Proc 2008; 40: 2303-2306.
53. de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies with "borderline rejection" and prospects for eliminating this category. Am J Transplant 2012; 12: 191-201.
54. Pesce JT, Ramalingam TR, Mentink-Kane MM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009; 5: e1000371.
55. Dharnidharka VR, Al Khasawneh E, Gupta S, et al. Verification of association of elevated serum IDO enzyme activity with acute rejection and low CD4-ATP levels with infection. Transplantation 2013; 96: 567-572.
56. Brandacher G, Cakar F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007; 71: 60-67.
57. Brandacher G, Margreiter R, Fuchs D., Implications of IFN-gamma-mediated tryptophan catabolism on solid organ transplantation. Curr Drug Metab 2007; 8: 273-282.
58. O'Donnell VB, Murphy RC., New families of bioactive oxidized phospholipids generated by immune cells: Identification and signaling actions. Blood 2012; 120: 1985-1992.